Why Axsome Therapeutics, Inc. (AXSM) Stock Fell 7.1% on Jul 31, 2026
What happened
Axsome Therapeutics fell 6.68% to $218.97 as broader biotech sector risk-off sentiment combined with profit-taking following the stock's recent strong run near 52-week highs, per the web_catalyst synthesis. Insider sales activity from earlier in the summer, including CEO share disposals in June, continues to weigh on sentiment. Volume of 481,577 shares is tracking at 0.83x the time-adjusted expected level.
AXSM earnings release scheduled for August 3, 2026; monitor for updates on commercial execution and pipeline milestones (notably AXS-12 NDA acceptance) that could catalyze a reversal.
Frequently asked questions
Why did Axsome Therapeutics, Inc. (AXSM) stock fall on Jul 31, 2026?
Axsome Therapeutics fell 6.68% to $218.97 as broader biotech sector risk-off sentiment combined with profit-taking following the stock's recent strong run near 52-week highs, per the web_catalyst synthesis. Insider sales activity from earlier in the summer, including CEO share disposals in June, continues to weigh on sentiment. Volume of 481,577 shares is tracking at 0.83x the time-adjusted expected level.
How much did AXSM stock fall on Jul 31, 2026?
AXSM fell 7.1% during the Jul 31, 2026 trading session.